Navigation Links
Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
Date:1/10/2011

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2011 at 1:30 p.m. PST (4:30 p.m. EST).  The conference is being held at Westin St. Francis Hotel in San Francisco.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.

The presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through January 27, 2011.  

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys has initiated a Phase IIb study of ANA598, the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended September 30, 2010.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
2. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
3. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
4. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
7. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
8. Anadys Retains Lazard as Strategic Advisor
9. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
10. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
Breaking Medicine Technology:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning services to communities in east Texas, is launching a regional ... Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... The ... communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to ... husband. , In early June of this year, Christina and her children returned from ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over ... in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for ... aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded ...
Breaking Medicine News(10 mins):